Top Key Companies for Radionuclide Drug Conjugates (RDC) Market: POINT Biopharma, Telix, ITM AG, Bayer AG, Novartis, Lantheus, Curium Pharma, Uihc Pet Imaging, Grand Pharma, BoomRay Pharmaceuticals, SmartNuclide Biopharma, Hengrui Medicine, Yunnan Baiyao Group, Sinotau, Hexin Pharmaceutical, Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd..
Global Radionuclide Drug Conjugates (RDC) Market Size was estimated at USD 200 million in 2022 and is projected to reach USD 218.82 million by 2028, exhibiting a CAGR of 1.51% during the forecast period.
Global Radionuclide Drug Conjugates (RDC) Market Overview And Scope:
The Global Radionuclide Drug Conjugates (RDC) Market Report 2025 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Radionuclide Drug Conjugates (RDC) utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2025 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
This Market Research Report provides a comprehensive analysis of the global Radionuclide Drug Conjugates (RDC) Market and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Radionuclide Drug Conjugates (RDC) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Radionuclide Drug Conjugates (RDC) market.
Global Radionuclide Drug Conjugates (RDC) Market Segmentation
By Type, Radionuclide Drug Conjugates (RDC) market has been segmented into:
Antibody Radionuclide Conjugates (ARC)
Peptide Radionuclide Conjugates (PRC)
Small Molecular Radionuclide Conjugates (SMRC)
By Application, Radionuclide Drug Conjugates (RDC) market has been segmented into:
Neuroendocrine Tumors
Prostate Cancer
Renal Cell Carcinoma
Regional Analysis of Radionuclide Drug Conjugates (RDC) Market:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape of Radionuclide Drug Conjugates (RDC) Market:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Radionuclide Drug Conjugates (RDC) market study focused on including all the primary level, secondary level and tertiary level competitors in the report.The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Radionuclide Drug Conjugates (RDC) market.
Top Key Companies Covered in Radionuclide Drug Conjugates (RDC) market are:
POINT Biopharma
Telix
ITM AG
Bayer AG
Novartis
Lantheus
Curium Pharma
Uihc Pet Imaging
Grand Pharma
BoomRay Pharmaceuticals
SmartNuclide Biopharma
Hengrui Medicine
Yunnan Baiyao Group
Sinotau
Hexin Pharmaceutical
Shenzhen Jianyuan Pharmaceutical Technology Co.
Ltd.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Radionuclide Drug Conjugates (RDC) Market by Type
5.1 Radionuclide Drug Conjugates (RDC) Market Overview Snapshot and Growth Engine
5.2 Radionuclide Drug Conjugates (RDC) Market Overview
5.3 Antibody Radionuclide Conjugates (ARC)
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Antibody Radionuclide Conjugates (ARC): Geographic Segmentation
5.4 Peptide Radionuclide Conjugates (PRC)
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Peptide Radionuclide Conjugates (PRC): Geographic Segmentation
5.5 Small Molecular Radionuclide Conjugates (SMRC)
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Small Molecular Radionuclide Conjugates (SMRC): Geographic Segmentation
Chapter 6: Radionuclide Drug Conjugates (RDC) Market by Application
6.1 Radionuclide Drug Conjugates (RDC) Market Overview Snapshot and Growth Engine
6.2 Radionuclide Drug Conjugates (RDC) Market Overview
6.3 Neuroendocrine Tumors
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Neuroendocrine Tumors: Geographic Segmentation
6.4 Prostate Cancer
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Prostate Cancer: Geographic Segmentation
6.5 Renal Cell Carcinoma
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Renal Cell Carcinoma: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Radionuclide Drug Conjugates (RDC) Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Radionuclide Drug Conjugates (RDC) Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Radionuclide Drug Conjugates (RDC) Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 POINT BIOPHARMA
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 TELIX
7.4 ITM AG
7.5 BAYER AG
7.6 NOVARTIS
7.7 LANTHEUS
7.8 CURIUM PHARMA
7.9 UIHC PET IMAGING
7.10 GRAND PHARMA
7.11 BOOMRAY PHARMACEUTICALS
7.12 SMARTNUCLIDE BIOPHARMA
7.13 HENGRUI MEDICINE
7.14 YUNNAN BAIYAO GROUP
7.15 SINOTAU
7.16 HEXIN PHARMACEUTICAL
7.17 SHENZHEN JIANYUAN PHARMACEUTICAL TECHNOLOGY CO.
7.18 LTD.
Chapter 8: Global Radionuclide Drug Conjugates (RDC) Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Antibody Radionuclide Conjugates (ARC)
8.2.2 Peptide Radionuclide Conjugates (PRC)
8.2.3 Small Molecular Radionuclide Conjugates (SMRC)
8.3 Historic and Forecasted Market Size By Application
8.3.1 Neuroendocrine Tumors
8.3.2 Prostate Cancer
8.3.3 Renal Cell Carcinoma
Chapter 9: North America Radionuclide Drug Conjugates (RDC) Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Antibody Radionuclide Conjugates (ARC)
9.4.2 Peptide Radionuclide Conjugates (PRC)
9.4.3 Small Molecular Radionuclide Conjugates (SMRC)
9.5 Historic and Forecasted Market Size By Application
9.5.1 Neuroendocrine Tumors
9.5.2 Prostate Cancer
9.5.3 Renal Cell Carcinoma
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Radionuclide Drug Conjugates (RDC) Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Antibody Radionuclide Conjugates (ARC)
10.4.2 Peptide Radionuclide Conjugates (PRC)
10.4.3 Small Molecular Radionuclide Conjugates (SMRC)
10.5 Historic and Forecasted Market Size By Application
10.5.1 Neuroendocrine Tumors
10.5.2 Prostate Cancer
10.5.3 Renal Cell Carcinoma
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Radionuclide Drug Conjugates (RDC) Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Antibody Radionuclide Conjugates (ARC)
11.4.2 Peptide Radionuclide Conjugates (PRC)
11.4.3 Small Molecular Radionuclide Conjugates (SMRC)
11.5 Historic and Forecasted Market Size By Application
11.5.1 Neuroendocrine Tumors
11.5.2 Prostate Cancer
11.5.3 Renal Cell Carcinoma
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Radionuclide Drug Conjugates (RDC) Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Antibody Radionuclide Conjugates (ARC)
12.4.2 Peptide Radionuclide Conjugates (PRC)
12.4.3 Small Molecular Radionuclide Conjugates (SMRC)
12.5 Historic and Forecasted Market Size By Application
12.5.1 Neuroendocrine Tumors
12.5.2 Prostate Cancer
12.5.3 Renal Cell Carcinoma
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Antibody Radionuclide Conjugates (ARC)
13.4.2 Peptide Radionuclide Conjugates (PRC)
13.4.3 Small Molecular Radionuclide Conjugates (SMRC)
13.5 Historic and Forecasted Market Size By Application
13.5.1 Neuroendocrine Tumors
13.5.2 Prostate Cancer
13.5.3 Renal Cell Carcinoma
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Radionuclide Drug Conjugates (RDC) Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Antibody Radionuclide Conjugates (ARC)
14.4.2 Peptide Radionuclide Conjugates (PRC)
14.4.3 Small Molecular Radionuclide Conjugates (SMRC)
14.5 Historic and Forecasted Market Size By Application
14.5.1 Neuroendocrine Tumors
14.5.2 Prostate Cancer
14.5.3 Renal Cell Carcinoma
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Radionuclide Drug Conjugates (RDC) Scope:
|
Report Data
|
Radionuclide Drug Conjugates (RDC) Market
|
|
Radionuclide Drug Conjugates (RDC) Market Size in 2025
|
USD XX million
|
|
Radionuclide Drug Conjugates (RDC) CAGR 2025 - 2032
|
XX%
|
|
Radionuclide Drug Conjugates (RDC) Base Year
|
2024
|
|
Radionuclide Drug Conjugates (RDC) Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
POINT Biopharma, Telix, ITM AG, Bayer AG, Novartis, Lantheus, Curium Pharma, Uihc Pet Imaging, Grand Pharma, BoomRay Pharmaceuticals, SmartNuclide Biopharma, Hengrui Medicine, Yunnan Baiyao Group, Sinotau, Hexin Pharmaceutical, Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd..
|
|
Key Segments
|
By Type
Antibody Radionuclide Conjugates (ARC)
Peptide Radionuclide Conjugates (PRC)
Small Molecular Radionuclide Conjugates (SMRC)
By Applications
Neuroendocrine Tumors
Prostate Cancer
Renal Cell Carcinoma
|
